INTRODUCTION {#S1}
============

The extraordinary architecture of neurons, with vast arbors of axons and dendrites, represents a challenge for the adequate supply and proper distribution of mitochondria. Axonal trafficking of mitochondria ensures that the neuron matches its needs for local energy production and calcium buffering capacity to appropriate spatial locations throughout this extended architecture. Axonal trafficking also plays a role in mitochondrial quality control by allowing newly synthesized mitochondria to replace or fuse with stationary, older mitochondria within the arbor, including those that are resident at synapses ([@R40]; [@R50]).

Defective axonal transport of mitochondria has been linked to several neurodegenerative disorders in animal and cellular models, including, but not limited to, multiple sclerosis ([@R30]; [@R54]), amyotrophic lateral sclerosis (ALS) ([@R32]), Charcot-Marie-Tooth type 2 disease ([@R41]), and Parkinson's disease ([@R24]; [@R62]; [@R63]). Defective axonal trafficking of mitochondria can impair mitochondrial function, produce energetic deficits, and lead to loss of appropriate synaptic signaling and neuronal degeneration ([@R19]; [@R38]; [@R48]; [@R56]). Therefore, enhancing mitochondrial transport may be a rational therapeutic strategy with potentially broad therapeutic impact. However, testing this hypothesis is hindered at present by our limited understanding of the signaling pathways that regulate the axonal transport of mitochondria as well as the lack of pharmacological tools for their manipulation.

Mitochondria are trafficked in animal cells by the Miro-milton motor-adaptor complex ([@R18]; [@R19]; [@R48]; [@R56]). Miro (RhotT1/2) is a mitochondrial GTPase on the outer membrane that interacts with the adaptor Milton (Trak1/2) ([@R18]). Milton recruits kinesin heavy chain (Kif5b) and the dynein-dynactin complexes to mitochondria ([@R18]). The Miro-milton complex receives inputs from signaling pathways that adjust mitochondrial transport to cellular needs. Such signals include Ca^2+^ ([@R49]; [@R61]; [@R66]), hypoxia ([@R35]), mitochondrial damage ([@R36]; [@R53]; [@R62]), the glucose/O-GlcNAc Transferase pathway ([@R10]; [@R25]; [@R44]), and Armcx ([@R37]). Mitochondrial motility is further refined by the abundance or localization of anchoring proteins, which can be either actin-myosin based ([@R6], [@R7]; [@R43]) or microtubule-syntaphilin based ([@R13]; [@R31]). The interplay of motors and anchors creates two pools of neuronal mitochondria: a predominantly motile pool that moves either anterograde or retrograde and a long-term stationary pool ([@R40]).

To explore the pathways that regulate axonal transport of mitochondria and to identify potentially druggable targets, we developed a high-content screening assay based on time-lapse imaging of mitochondria. We used this platform to perform an unbiased compound screen using a "mechanism of action" library. We found enhancers and suppressors of axonal trafficking of mitochondria and proceeded to identify relevant cellular targets of our enhancer molecules using both rodent and human neurons. Finally, we also show that manipulating these targets can reverse defective mitochondrial trafficking in motor neurons generated from a patient-derived induced pluripotent stem cell (iPSC) line carrying an SOD1^+/A4V^ ALS mutation.

RESULTS {#S2}
=======

PATHS: Particle Analysis and Tracking for High-Throughput Screening {#S3}
-------------------------------------------------------------------

Analysis of axonal transport typically involves constructing kymographs, two-dimensional representations of movement, where the location of a mitochondrion (or other particle) is coded along the x axis and the time is represented along the y axis ([@R60]). While kymographs provide rich information about the motile behavior of individual particles, their analysis is laborious, time consuming, restricted to individual axons, potentially subject to bias in the selection of axons, and only captures the behavior of tens of mitochondria per axon. Kymography, therefore, cannot be used as a readout in large-scale, unbiased screening; consequently, we set out to develop a particle-tracking method for automated quantitation of axonal transport that would be compatible with high-throughput screening.

Particle tracking is a hard task for automation; challenges include high particle density, particle merging and splitting, and temporal disappearance ([@R26]). Many of these problems can be addressed by careful optimization of the fluorescent label density and time-lapse frequency, as well as by the choice of the tracking algorithm. The linear assignment problem (LAP) tracking method ([@R27]) is an algorithm well suited for automated screening. The open-source CellProfiler biological analysis package is one of the few options for combining cellular identification and the ability to process large numbers of time-lapse movies for high-throughput screening ([@R3]) that also incorporates LAP-based tracking. Therefore, we used CellProfiler to develop a pipeline for automated tracking of mitochondria.

We dissociated E18 rat hippocampal neurons and cultured them on 96-well plates for 6--7 days (DIV6-7) before transfecting a subset of the cells (approximately 20%--30%) with MitoDsRed, a red fluorescent protein localized to the mitochondrial matrix (see [STAR Methods](#S9){ref-type="sec"}; [Figure S1B](#SD1){ref-type="supplementary-material"}). Two days later (DIV8-9), labeled mitochondrial movement was observable ([Video S1](#SD2){ref-type="supplementary-material"}) and a set of time-lapse series was collected on an automated imaging platform. We used these images to create an analysis pipeline within CellProfiler combined with a custom MATLAB script that we called PATHS (Particle Analysis and Tracking for High-throughput Screening). PATHS starts by identifying mitochondria in each frame of a time-lapse sequence ([Figure 1A](#F1){ref-type="fig"}). In order to focus our analysis exclusively on mitochondria traveling along neurites, we used a size-based mask to identify the small (1--10 μm in size) individual mitochondria that are typically observed in axons and secondary dendrites and to eliminate from the analysis larger mitochondria and mitochondrial networks, which correspond to the highly fused mitochondria of somato-dendritic regions ([@R8]). The mask also eliminated non-neuronal cells and fluorescent debris ([Figure S1A](#SD1){ref-type="supplementary-material"}).

The ability to track faithfully the paths of moving mitochondria from frame to frame depends critically on the spacing between objects; the more cluttered the field, the greater the difficulty in tracking ([@R26]). Because the majority of mitochondria (typically 70%--80%) in rat hippocampal cultures remain stationary for long periods of time ([@R40]), we found that masking the stationary mitochondria from the images substantially improved the accuracy of tracking the moving mitochondria. For (x,y) locations located within a stationary mitochondrion, the fluorescent intensity values will be consistently high across all frames, whereas for motile mitochondria, the intensity will be transiently high at an (x,y) location as the mitochondria pass through. PATHS takes advantage of this property to sort objects into motile and stationary categories by taking a minimum-intensity projection of the time-lapse series (i.e., the minimum intensity value across the frames at each (x,y) location), such that only the stationary mitochondria remain visible ([Figure S1C](#SD1){ref-type="supplementary-material"}). Subsequently, PATHS identifies and masks the stationary mitochondria from each frame of the time-lapse series ([Figure 1B](#F1){ref-type="fig"}) and then tracks the motile mitochondria through the decluttered fields of view using the LAP algorithm ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}; [Video S2](#SD3){ref-type="supplementary-material"}).

Our algorithms extract three descriptors of motility: percent motile (the proportion of motile organelles per well), the integrated distance traveled for each motile organelle (the length of travel, or the sum of all movements, including changes in direction), as well as the displacement (absolute distance between the point of initiation of travel and the final destination) for each motile organelle. We evaluated all three parameters using the Z-prime statistic to identify which parameter is most sensitive to changes in mitochondrial motility by known factors that enhance or decrease their axonal transport. To decrease motility as a positive control, we used calcimycin, a calcium ionophore that arrests mitochondria ([@R60]). We seeded 96-well plates with rat hippocampal neurons, transfected them with mito-DSred at DIV07 and incubated 48 of the wells for a brief period (15 min) with 10 mM calcimycin at DIV09. In each well, approximately 40,000 mitochondria were imaged. As expected, PATHS detected fewer mitochondrial tracks in the calcimycin-treated wells ([Figure 1E](#F1){ref-type="fig"}, blue lines) and a reduced percent of motile mitochondria and *Z* score of percent motile ([Figure 1F](#F1){ref-type="fig"}). Calcimycin treatment, by decreasing the integrated distances and displacement, enhanced Kolmogorov-Smirnov (KS) values and *Z* scores for both parameters ([Figure 1G](#F1){ref-type="fig"}). We then optimized cell culture conditions, plate type, transfection protocol, control molecules, and assay kinetics with a target of Z-prime factor Z′ \> 0.5 ([Figure S1B](#SD1){ref-type="supplementary-material"}). When we calculated the Z prime for percent motile, the KS of integrated distance, and the KS of displacement, we found that the KSs of integrated distance and displacement were the most sensitive descriptors, superior to percent motile and yielding Z-prime values higher than 0.5, indicating that the ability of these parameters to distinguish treated and untreated wells was sufficiently robust for screening. The ability to monitor and quantify the movement of approximately 40,000 mitochondria was crucial to the sensitivity of the assay.

To test our ability to detect enhanced motility, we used neurons derived from *syntaphillin* knockout mice (SNPH^−/−^) ([@R31]), which show large increases in axonal trafficking of mitochondria relative to control C57Bl6 mice. We seeded 48 wells of a 96-well plate with hippocampal neurons dissected from each of these genotypes, transfected with Mito-DsRed at DIV06, and imaged them at DIV08. We checked plates under a fluorescent microscope before running the assay to ensure transfection and also monitored cell viability by taking a short time-lapse sequence of a "negative control" well, making sure mitochondria were motile. Upon analysis by our automated pipeline, *SNPH*^−/−^ neurons showed a significantly higher percentage of motile mitochondria as well as integrated distance and displacement as compared to control *SNPH*^+/+^ neurons ([Figures 1H](#F1){ref-type="fig"}--[J](#F1){ref-type="fig"}). Again, the KS integrated distance and displacement were equally sensitive, and both were more sensitive than percent motile. Thus, the platform can identify both enhanced and diminished mitochondrial trafficking along neurites, can detect changes in response to genetic or chemical perturbation, and is robust enough to be used for high-content screening.

Compound Screening Identifies Six Enhancers of Mitochondrial Transport {#S4}
----------------------------------------------------------------------

We screened two bioactive chemical libraries: the Biomol collection (480 compounds) and the Selleck Bioactive collection (2,800 compounds). Both libraries contain well-characterized, potent compounds covering a large collection of druggable targets (see [STAR Methods](#S9){ref-type="sec"}). Each chemical library was screened in two replicates. We dissociated rat hippocampal neurons from E18 embryos, cultured the neurons on 96-well plates, transfected with Mito-DsRed at DIV6-7, and imaged at DIV8-9. At this stage the neurons are still growing, but already have functional synapses ([@R1]; [@R21]). Compounds were added at a single concentration (3 μM) 1 h prior to imaging. For imaging, time-lapse series of \~50 frames were acquired with a 20× objective from four different fields in each well of a 96-well plate. With this protocol, each plate was imaged for a total of 2 h (see [STAR Methods](#S9){ref-type="sec"} for details). An average *Z* score of 3 or higher in both rounds of screening was taken as the threshold for each descriptor to qualify a compound as a hit. We used the KS of integrated distance as the descriptor for Z-score calculations. During the screen, we continued to use calcimycin as a positive control, which consistently yielded an overall Z-prime value of 0.5 or higher. At the end of the assay, the cells were incubated with the mitochondrial potentiometric dye tetramethylrhodamine methyl ester (TMRM). Levels of TMRM fluorescence were used as an orthogonal screen to filter out hits that were decreasing motility via mitochondrial depolarization rather than via regulatory pathways.

The distribution of *Z* scores, as presented in [Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}, identified 38 suppressors and 8 enhancers of motility. Suppressors covered a variety of chemical classes ([Figure S2A](#SD1){ref-type="supplementary-material"}), but all but two suppressing compounds either were known to depolymerize microtubules (vincristine and vinblastine) or significantly decreased mitochondrial membrane potential as determined from TMRM intensity ([Figure S2B](#SD1){ref-type="supplementary-material"}). The latter are likely to suppress motility by depleting axonal ATP or activating the PINK1/Parkin pathway ([@R62]). The compounds that did not affect TMRM or microtubules were NMS-873, a valosin-containing protein (VCP)/p97 inhibitor ([@R39]), and NH125, a regulator of eEF-2 kinase ([@R9]; [@R14]) ([Figures S2C](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). Their mechanism is unclear, as these had not previously been identified as suppressors of mitochondrial transport.

We focused on the compounds that increased motility. We found, and subsequently confirmed by retesting, two actin depolymerizers (Latrunculin B, effective concentration \[EC\]~50~ = 800 nM, and Cytochalasin B, EC~50~ = 300 nM), three kinase inhibitors (BMS-754807, EC~50~ = 350 nM; Hesperadin, EC~50~ = 230 nM; and TAK-901, EC~50~ = 540 nM), and one peptidase inhibitor (Ala-Ala-Phe-chloromethylketone \[AAF-CMK\], EC~50~ =1.9 μM) ([Figure 2C](#F2){ref-type="fig"}). Two other initial positives, paclitaxel and the bioactive lipid 24(S)-hydroxycholesterol, failed upon retesting. Dose response curves with the six active enhancers showed that all compounds acted at sub-micromolar concentrations, with the exception of AAF-CMK, which acted at low micromolar concentrations ([Figures 2D](#F2){ref-type="fig"}--[2I](#F2){ref-type="fig"}). F-actin has been observed previously to inhibit axonal transport of mitochondria ([@R7]) and thus identification of Latrunculin B and Cytochalasin B validated the screen.

TPP1 Is a Negative Regulator of Mitochondrial Motility in Hippocampal Axons {#S5}
---------------------------------------------------------------------------

AAF-CMK is a serine protease inhibitor that reversibly inhibits the lysosomal enzyme Tripeptidyl Peptidase 1 (TPP1) ([@R15]) and irreversibly inhibits the post-proteasome exopeptidase tripeptidyl peptidase II (TPPII) ([@R17]). AAF-CMK also marginally inhibits the chymotrypsin-like activity of the proteasome ([Figure 3A](#F3){ref-type="fig"}) ([@R28]). To distinguish among these potential targets, we used available small molecule inhibitors for each and small hairpin RNA (shRNA) against TPP1 and TPP2. We excluded TPP2 as the relevant target because an effective TPP2 shRNA ([Figure S3A](#SD1){ref-type="supplementary-material"}) neither enhanced mitochondrial transport nor occluded the effect of AAF-CMK ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Furthermore, butabindide, a potent inhibitor of TPP2 with a Ki = 7 nM ([@R47]), failed to mimic the efficacy of AAF-CMK ([Figure 3D](#F3){ref-type="fig"}). We similarly ruled out the contribution of the proteasome because inhibitors of the chymotrypsin-like activity of the proteasome such as carfilzomib ([Figure 3E](#F3){ref-type="fig"}) did not enhance mitochondrial motility. In contrast, two shRNA against TPP1 ([Figure S3B](#SD1){ref-type="supplementary-material"}) potently enhanced mitochondrial transport and occluded any further effect of AAF-CMK ([Figures 3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). Conversely, overexpression of TPP1 suppressed mitochondrial movement ([Figure 3H](#F3){ref-type="fig"}). Thus, the lysosomal enzyme TPP1 is a negative regulator of mitochondrial trafficking, although the mechanism by which it influences mitochondria remains unclear.

Aurora B Regulates Mitochondrial Motility in Hippocampal Axons {#S6}
--------------------------------------------------------------

The three kinase inhibitors (BMS-754807, Hesperadin, and TAK-901) share targets within the Aurora kinase family (Aurora A, B, and C). BMS-754807 was originally developed as an insulin-like growth factor (IGFR) inhibitor with an inhibitory concentration (IC)~50~ of 1.8 nM/1.7 nM in cell free assays, although it can inhibit other kinases, including Aurora Kinase A (AurKA) with IC~50~ = 9 nM and Aurora Kinase B (AurKB) with an IC~50~ = 25 nM ([@R2]). Two selective inhibitors of IGFR (Picopodophyllin and OSI-906) were included in the screen but did not enhance mitochondrial motility. Hesperadin inhibits Aurora Kinase B with IC~50~ = 250 nM in a cell-free assay ([@R22]). TAK-901 inhibits Aurora Kinase A with IC~50~ = 21 nM and Aurora Kinase B with IC~50~ = 15 nM. We therefore focused on the Aurora family as the likely relevant cellular substrate for these hits. To test this hypothesis, we first re-examined our initial screen to determine the effects of all the Aurora family inhibitors that had been present in our libraries. Three additional compounds, Danusertib, CYC116, and AMG-900 ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}), had enhanced mitochondrial transport in both replicates although they had not met our original selection criteria because in at least one of the replicates the enhancement of motility did not reach the threshold of *Z* score = 3. All 6 positives were either pan-Aurora inhibitors or Aurora Kinase B inhibitors. Aurora Kinase C is expressed primarily in the germline and so we used shRNAs against Aurora Kinases A and B ([Figure S4C](#SD1){ref-type="supplementary-material"}) to determine the relevant cellular target. Knockdown of Aurora Kinase B, but not of Aurora Kinase A, both mimicked and occluded the effect of the Aurora Kinase B inhibitor Hesperadin on percent motile ([Figures 4A](#F4){ref-type="fig"}--[4D](#F4){ref-type="fig"}) and integrated distance ([Figures 4E](#F4){ref-type="fig"}--[4G](#F4){ref-type="fig"}). Furthermore, Barasertib, a selective Aurora Kinase B inhibitor with IC~50~ = 0.37 nM in a cell-free assay and \~3,700-fold more selective for Aurora Kinase B over Aurora Kinase A ([@R65]) also enhanced mitochondrial transport in a dose-dependent manner ([Figure 4H](#F4){ref-type="fig"}). In contrast, the more selective Aurora Kinase A inhibitors in the compound screen did not enhance mitochondrial motility ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}). The effect of Aurora Kinase B knockdown on mitochondrial transport was reversed by overexpression of an shRNA-resistant Aurora Kinase B construct, but not by the kinase-dead form of Aurora Kinase B ([Figure 4I](#F4){ref-type="fig"}). Conversely, Aurora Kinase B overexpression suppressed mitochondrial transport ([Figures 4J](#F4){ref-type="fig"}--[4L](#F4){ref-type="fig"}). Thus, Aurora Kinase B is a negative regulator of mitochondrial transport in hippocampal neurons.

Because PATHS cannot unambiguously differentiate between axonal and dendritic mitochondria, nor between anterograde and retrograde movement, we tested the effects of Aurora Kinase B inhibition using traditional kymography in axons ([Figure 5A](#F5){ref-type="fig"}). Hesperadin, a selective Aurora Kinase B inhibitor, was added 1 h before acquiring 5-min videomicroscopy series from which kymographs were constructed. Hesperadin enhanced the percent of axonal mitochondria that were motile as well as the average time spent in retrograde motion ([Figures 5B](#F5){ref-type="fig"}--[5D](#F5){ref-type="fig"}). No changes in anterograde motility or mitochondrial density were observed ([Figure 5E](#F5){ref-type="fig"}). Neurons transfected with shRNA against Aurora Kinase B also showed an increased percent motile and time mitochondria spent in motion ([Figures 5F](#F5){ref-type="fig"} and [5G](#F5){ref-type="fig"}); however, this long-term reduction in Aurora Kinase B enhanced both anterograde and retrograde movements ([Figures 5H](#F5){ref-type="fig"} and [5I](#F5){ref-type="fig"}) and reduced the density of stationary mitochondria ([Figure 5J](#F5){ref-type="fig"}). Neither Hesperadin nor knockdown of Aurora Kinase B altered the motility of late endosomes as determined by the tracking of late endosomes ([Figures S5A](#SD1){ref-type="supplementary-material"}--[S5D](#SD1){ref-type="supplementary-material"}).

Hits Enhance Mitochondrial Transport in Human Cortical Neurons and Alleviate Mitochondrial Transport Defects in ALS Motor Neurons {#S7}
---------------------------------------------------------------------------------------------------------------------------------

We next asked if the screen was able to identify mechanisms relevant to axonal transport in human neurons. We first tested whether the pathways identified in our screen were conserved in neurons differentiated from iPSCs with a protocol that generates \~90% pure cortical neurons ([@R67]; [Figure 6A](#F6){ref-type="fig"}). Neurons were transduced with lentivirus encoding Mito-DsRed, and treated with a representative compound of each class of hit (Latrunculin, Hesperadin, and AAF-CMK) before automated imaging and analysis with PATHS. All three compounds significantly enhanced mitochondrial transport ([Figures 6B](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}). Subsequent kymography of axons revealed that inhibition of Aurora Kinase B increased both anterograde and retrograde mitochondrial motility ([Figures 6D](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"}). Thus, the three classes of hits from our screen (inhibitors of F-actin, TPP1, and Aurora Kinase B) appear to act on mitochondrial motility through mechanisms that are conserved between rat hippocampal and human cortical neurons.

Previous studies have demonstrated that the dominant ALS mutation SOD1^A4V^ reduces mitochondrial transport in motor-neuron axons ([@R32]). To determine whether the hit compounds have the potential to restore defective mitochondrial trafficking in diseased neurons, we examined transport in human motor neurons derived from an iPSC line from a SOD1^+/A4V^ patient ([@R35]). We differentiated motor neurons from the SOD1^+/A4V^ line as well as from the transcription activator-like effector nuclease (TALEN)-corrected isogenic control, transduced neurons with a lentivirus coding for mito-DSred, and performed imaging on our platform followed by PATHS analysis ([Figure 6F](#F6){ref-type="fig"}). Our automated analysis confirmed the defect in mitochondrial motility that had previously been described in these cells by kymographic analysis ([@R32]) ([Figures 6G](#F6){ref-type="fig"} and [6H](#F6){ref-type="fig"}). Treatment with latrunculin, Hesperadin, and AAF-CMK each increased mitochondrial motility in the +/A4V neurons ([Figure 6I](#F6){ref-type="fig"}). A more detailed analysis by kymography found that Aurora Kinase B inhibition with Hesperadin restored mitochondrial transport back to the levels of the TALEN-corrected control ([Figures 6J](#F6){ref-type="fig"} and [6K](#F6){ref-type="fig"}).

DISCUSSION {#S8}
==========

We performed a screen to identify druggable regulators of axonal transport and thereby uncover cellular targets that influence mitochondrial movement. We show that (1) axonal transport can be used as an endpoint in an image-based screening campaign; (2) three classes of compounds and their targets can enhance mitochondrial transport in primary neurons; and (3) the targets of active compounds are functionally conserved in human neurons and can be targeted to reverse mitochondrial transport defects in ALS motor neurons.

The development of PATHS, which combines a tracking algorithm and data analysis package, enabled exploration of the druggable space for regulators of mitochondrial transport. This method allowed precise quantitative description of motility parameters for tens of thousands of individual mitochondria per condition, a scale that is orders of magnitude higher in sampling power than kymography can achieve. Kymography serves as a complementary secondary assay because, although limited in throughput, it offers information on the direction of transport, and can unambiguously identify specifically axonal regulators because mitochondria traveling along secondary dendrites are excluded in the analysis.

The results of our screen validate the approach. As expected, mitochondrial motility was arrested by compounds that depolarized mitochondria and by vincristine and vinblastine, which disrupt microtubules ([@R29]). F-actin is known to inhibit mitochondrial trafficking ([@R6]; [@R33]; [@R43]) and we identified as enhancers of motility two compounds that destabilize the F-actin cytoskeleton: latrunculin, which sequesters globular monomeric actin, and cytochalasin, which blocks the addition of G-actin to the growing end of the microfilament. An attractive hypothesis is that mitochondria use F-actin as a structural scaffold onto which they can anchor in response to particular stop signals. As appropriate for such a function, F-actin is found in periodic rings along the axonal shaft ([@R64]) and is highly enriched at nascent presynaptic sites ([@R55]). It is important to note, however, that in our study, as in previous studies, the effect is subtle: it does not mobilize the majority of the stationary mitochondria and much remains to be learned about the relative importance and interplay of different mechanisms that arrest or anchor mitochondria. Indeed, none of the compounds found in the screen alter mitochondrial motility as dramatically as the knockout of syntaphilin ([@R31]), a major mitochondrial anchor. This likely reflects that there are many mechanisms working in parallel to govern the balance between stationary and motile mitochondria. These pathways will include F-actin, myosins, Ca^2+^, glucose availability, syntaphilin, PINK1, and more. A drug that impacts a single pathway among the many involved is likely to cause only a modest change in the percent motile. The pathways we found are thus likely to modulate mitochondrial motility without fundamentally disrupting the key mechanisms of motility and anchoring.

The screening methods described here can have applications beyond the particulars of our screen. Although we chose to meet the need for large numbers of neurons of consistent quality by screening on rodent hippocampal neurons, we confirmed that our screen identified hits and druggable targets that are also effective on human neurons ([Figure 6](#F6){ref-type="fig"}). The screening method is applicable to genetic screens as well as the acute drug effects we assayed. PATHS would, for example, be very suitable for using axonal transport as an endpoint in a CRISPR-based genetic screen in which iPSC-progenitor lines are mutated and then differentiated to neurons prior to screening. In addition, the algorithms are applicable to cargos other than mitochondria, as long as the experiment is designed with attention to object density and speed so as to allow robust automated tracking ([@R26]). The screen is also applicable to libraries larger than those we tested. However, because the screen involves taking thousands of short time-lapse images from each well, escalation to a larger plate size would need to take into account the delay between the moment a compound is added and the moment where mitochondria are imaged. Larger compound screens would thus require careful design of drug dosage and duration of treatment. Also, because the overall level of motility declines as the population of synaptically anchored mitochondria increases ([@R34]), additional optimization of PATHS would be required to image mitochondrial motility in more mature cultures.

Although we focused on enhancers of motility, two compounds arrested mitochondria without affecting TMRM intensity and these may point to regulatory pathways of mitochondrial motility: NMS-873 is a VCP/p97 inhibitor ([@R39]) and NH-125 is a putative regulator of eEF2 kinase ([@R9]; [@R14]). VCP/p97 is implicated in mitochondrial clearance by the PINK1/Parkin pathway and in removal of mitofusin ([@R57]), but no mechanistic connection of either NMS-873 or NH125 to mitochondrial transport has not been reported at this time.

TPP1 inhibition by AAF-CMK or knockdown by RNAi enhanced mitochondrial motility. TPP1 is a lysosomal enzyme, and loss of function mutations in the gene are causally linked to a familial lysosomal storage disorder ([@R15]). How TPP1 regulates mitochondrial transport remains unclear but lysosomal dysfunction and mitochondrial transport share linkages to Parkinson's disease ([@R16]; [@R24]; [@R53]). The pathological consequences of loss of TPP1 activity suggest that it is not itself an attractive therapeutic target in ALS, but further elucidation of the pathway by which it regulates mitochondrial motility might identify targets downstream that did not cause lysosomal storage defects.

By both pharmacologic and knockdown methods, we found that Aurora Kinase B is a regulator of mitochondrial transport. Aurora Kinase B has a well-characterized role in orchestrating cell division and cytokinesis, but the role of Aurora Kinase B in differentiated cells is largely unexplored. Recently, Aurora Kinase B has been found to be expressed in post-mitotic neurons of the zebrafish brain and spinal cord, where it regulates axonal outgrowth and regeneration ([@R20]). Aurora Kinase B is significantly upregulated upon axotomy ([@R42]) and may mediate regenerative sprouting, and yet, paradoxically, axon regeneration involves enhanced mitochondrial trafficking ([@R4], [@R5]; [@R51]) and yet Aurora Kinase B decreased mitochondrial traffic in our study. An intriguing possibility is that Aurora Kinase B participates in a pathway that positions stationary mitochondria at critical places such as branch points, nascent synapses, and growth cones ([@R13]). As such, it could act in regenerating axons to capture the increased axonal flux of mitochondria at necessary junctures. Acute pharmacological inhibition of Aurora Kinase B preferentially stimulated retrograde transport ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}), while sustained inhibition with shRNA promoted both directions ([Figures 5J](#F5){ref-type="fig"} and 5K). Therefore, it is possible that AuKB has a preferred substrate in the retrograde motor and a less direct, or possibly compensatory, effect on anterograde movement. Thus, Aurora Kinase B may promote axon regeneration by biasing transport down the axon via suppression of retrograde movement. Aurora Kinase A has been shown to disrupt the association of kinesin with mitochondria in dividing cells ([@R12]), but the mechanism by which Aurora Kinase B regulates mitochondrial trafficking is presently unclear.

Extensive evidence links neurodegeneration to defects in mitochondrial transport, including the evidence presented here for the SOD1^A4V/+^ neurons. An appealing hypothesis, therefore, is that improving mitochondrial transport and thereby improving the energy supply and Ca^2+^-buffering capacity of axons may prolong the life and function of affected neurons and ameliorate progression of the disease. The particular targets identified here, however, may not be ideal therapeutics: TPP1 inhibition is likely to cause deleterious side effects ([@R15]) and Aurora Kinase B inhibitors, though investigated for chemotherapeutic purposes, have counterindicating toxicities due to their effects on dividing cells. The success of the screen in identifying pathways and in demonstrating that hit compounds can be effective in improving transport in human neurons and in a pathogenic genetic background indicates that a broader application of the screening protocol may be a productive line of investigation. The arrest of mitochondria at important sites, such as synapses, is likely to be as important for neuronal function as sufficient levels of trafficking. A drastic increase in mitochondrial motility, as in the case of syntaphilin knockout mice, might therefore diminish mitochondrial supply at crucial sites and this may explain the failure of syntaphilin knockout to be effective in a mouse model of ALS ([@R68]). The ability of the hits identified here to restore normal levels of transport rather than to mobilize most axonal mitochondria ([@R68]) may be a valuable feature of a pharmacological approach. Nevertheless, there is not, as yet, a critical test of the hypothesis that improving mitochondrial transport can extend neuronal survival in ALS and therefore the therapeutic potential of this approach remains uncertain.

In summary, we developed a unique assay that overcomes the inherent difficulty of tracking motile objects in high throughput. The assay is sensitive and successfully identified regulators of axonal transport of mitochondria. The finding that TPP1 and Aurora Kinase B kinase play a previously unsuspected role in neurons by regulating mitochondrial trafficking has created an opportunity to explore the cell biological mechanisms of these pathways. Finally, because defective axonal transport in ALS motor neurons is restorable upon treatment with the hit compounds here identified, the necessary tools are now available to test the potential of modulating axonal transport as a neuro-protective intervention.

STAR★METHODS {#S9}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
---------------------------------------

### Materials Availability Statement {#S11}

Plasmids generated in this study are available upon request. Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact, Thomas L. Schwarz (<Thomas.schwarz@childrens.harvard.edu>). An MTA agreement prevents us from sharing the Syntaphilin KO mouse ([@R31]) and the GON0515-03 \#5 iPSC line.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Animal Models {#S13}

Time-pregnant SAS Sprague Dawley rats were obtained from Charles River Laboratories. Syntaphilin KO homozygous mice received from Zu-Hang Sheng (C57BL/BJ background) were crossed to C57BL/BJ mice (\#000664, The Jackson Laboratory). Heterozygotes were then crossed to obtain homozygotes littermates. SNPH KO or WT/WT homozygous littermates were intercrossed again and pregnant females were dissected obtain mouse primary hippocampal cultures from embryos. All animal procedures were approved by the Institutional Animal Care Committee at the Boston Children's Hospital.

### Primary Cells, Cell Lines and iPSCs {#S14}

Primary hippocampal neurons were isolated from E18 embryos according to standard procedures and cultured in Neurobasal Medium (\#21103049) supplemented with GIBCO B27 in 5% CO2 at 37C. HEK293T cells were obtained from ATCC and cultured in DMEM+5%FBS. Cells were used between P1-P13. The iPSC line used to generate cortical neurons, GON0515-03 \#5, was derived from peripheral blood mononuclear cells of a normal individual using CytoTune-iPS Sendai Reprogramming Kit (ThermoFisher, \#A1378001) at the BCH Human Neuron Core. This iPSC line has a normal karyotype, and expresses pluripotency markers, and was negative for mycoplasm (Lonza MycoAlert readings A = 158, B = 77, B/A ratio = 0.487). The iPSC lines 39b SOD+/A4V and 39b SOD+/+, previously described in [@R59] were tested negative for mycoplasma. The lines were maintained at 37°C, 5% CO~2~ on Matrigel (BD Biosciences) with mTeSR1 media (Stem Cell Technologies). iPSCs were karyotyped before genome engineering. Culture Medium was changed every 24 h and cells were passaged by accutase (Innovative Cell Technologies) as required.

METHOD DETAILS {#S15}
--------------

### Plasmids {#S16}

Mito-DsRed (pDsRed2-Mito) was a gift of G. Hajnoczky. Rab7-GFP was a gift from Richard Pagano (Addgene plasmid \# 12605). FLAG-TPP1, human AurKB and rat AurKB were purchased from OriGene (9620 Medical Center Drive, Suite 200, Rockville, MD 20850). CMV-Mito-DsRed and Synapsin-Mito-DsRed expressing lentivirus were produced at the BCH viral Core. Human Aurora B K106R mutant (kinase dead) was synthetized using pCMV-Myc-DDK-AurkB backbone using Q5® Site-Directed Mutagenesis Kit (NEB). shRNA expressing lentivirus and coding plasmids were obtained from Origene. Rat TPP1, TPP2 and AurKB shRNAs were selected for their efficacy based on western blots ([Figures S3A](#SD1){ref-type="supplementary-material"}, [S3B](#SD1){ref-type="supplementary-material"}, and [S4C](#SD1){ref-type="supplementary-material"}). Transfection efficiency of shRNAs was verified by fluorescent microscopy, as the plasmids also express GFP. Co-transfection efficiency with Mito-DsRed was almost 90% in primary neuronal cultures. All plasmids were sequence-verified prior to use. The lentiviral FS_MitoDsRed plasmid was generated from the pLV-MitoDsRed (Addgene \#44386) and a homemade FSGW backbone where a human synapsin promoter (GGCCCTGCGTATGAGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGGGGTGCCTACCTGACGACCGACCCCGACCCACTGGACAAGCACCCAACCCCCATTCCCCAAATTGCGCATCCCCTATCAGAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGTGCCTTCGCCCCCGCCTGGCGGCGCGCGCCACCGCCGCCTCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCCCCCGCAAACTCCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCCGCCGGCCCAGCCGGACCGCACCACGCGAGGCGCGAGATAGGGGGGCACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCGTGCCTGAGAGCGCAG) was cloned to the FUGW backbone to replace the original ubiquitin promoter. The MitoDsRed fragment was PCR amplified from pLV-MitoDsRed, and assembled with the FSGW backbone using Gibson cloning (NEB: E2611S). Lentiviral particles expressing the human synapsin promoter driven MitoDsRed reporter were packed and concentrated through Boston Children's Hospital Viral Core.

### Western Blotting {#S17}

Cells were harvested in lysis buffer (0.05M Tris pH7.5,150mM NaCl, 1% Triton, 0.1mM PMSF, 1:500 Calbiochem protease inhibitor cocktail set III). For quantification, membranes were incubated with fluorescent secondary antibodies and images were acquired on Typhoon laser scanner (GE Healthcare, Wilmington, MA) within the linear range. If not indicated, western blots are representative of at least three independent transfections.

### Compound Screen {#S18}

E18 rat hippocampal neurons were routinely seeded at 30,000 cells/well on Greiner Cellstar 96 well plates, cat\# 655090 (4238 Capital Drive, Monroe, NC 28110) coated with 20 μg/mL poly-L-Lysine (Sigma Aldrich) and 3.5 ug/mL laminin (ThermoFisher Scientific) overnight at room temperature, and maintained in Neurobasal medium (ThermoFisher Scientific) supplemented with B27 (GIBCO), L-glutamine, and penicillin/streptomycin. Cells in each well were transfected with 0.3 μg Mito-DSred at DIV6-7 using 0.8 μL Lipofectamine 2000 (ThermoFisher Sientific, Waltham, MA 02451) and imaged at DIV8-9. Small molecule libraries were obtained from ICCB-Longwood (<https://iccb.med.harvard.edu/>). Compounds were pin-transferred into Greiner 384 well plates (cat\#784201) at the ICCB-Longwood facility and immediately added to the cells using Agilent Bravo Liquid Handling Platform (Agilent, 5301 Stevens Creek Blvd, Santa Clara, CA 95051). Cells were incubated with compounds at 3μM for 1 h before and during time-lapse imaging. The plates were dosed and imaged one at a time. Z-scores were calculated for each parameter using the formula Z = (x-μ)/σ. A cutoff of Z-score \> 3 in KS integrated distance was used to identify hits. Dose-response curves were performed using either six to eight quarter-log concentration increments with maximum values reaching the concentration used in the screen (3 μM). Concentrations (in nM) were transformed to log nM and values were internally normalized from low to high as percentage activity. Curve fitting was performed in GraphPad Prism using log(agonist) versus normalized response -- variable slope --curve fitting. Values presented in [Figure 2](#F2){ref-type="fig"} were collected from an average of three to six well replicates from one 96-well plate.

### Kymography {#S19}

Rat hippocampal neurons were isolated according to standard procedures and cultured as in [@R44]. Briefly, neurons were obtained from E18 embryos, plated at 150 × 10^3^ on 12-mm glass coverslips (Bellco Glass) or on Greiner Cellstar 96 well plates coated and maintained as above. Neurons were transfected at DIV07-8 and imaged at DIV9-10 at 5% CO2 and 37C using NikonTiE Eclipse 20X. Time-lapse imaging was performed every 2 s for \~300 s. Movies were analyzed using the Kymolyzer macro for ImageJ developed by the laboratory. In all kymographs, anterograde motility is to the right, retrograde motility is to the left.

### Immunofluorescence {#S20}

Neurogenin2-induced cortical neurons were fixed with 4% paraformaldehyde (PFA) by adding 50ul 8% PFA to 50ul media and incubating for 20 min at room temperature. After three washes with 1X PBS, the cells were blocked with blocking reagent (2% Bovine Serum Albumin, 5% normal goat serum, 0.1% Triton X-100 in 1XPBS) for 1 h at room temperature and immunostained with primary antibody overnight at 4C. The next day, cells were washed three times with 1X PBS before staining with secondary antibodies. After a final three washes with 1X PBS, cells were stored in 1X PBS + 0.02% sodium azide.

### Time-Lapse High-Content Imaging of Mitochondrial Transport {#S21}

Neurons were imaged on an ArrayScan XTI imaging platform (ThermoFisher Sientific, Waltham, MA 02451). 30 frames per field were acquired at the maximum speed of 2 Hz. Four fields were imaged per well of a 96-well plate containing 30,000 rat hippocampal neurons/well at DIV08-09 using a 20X objective with 2x2 binning. To minimize well to well differences in exposure to compounds, the fields were imaged according to this sequence: field 1 was imaged in every well before returning to the start of the plate and imaging field 2 in every well, and similarly for fields 3 and 4. Imaging one field per well for 96 wells took \~30 min when acquiring 30 frames at 2Hz in each well. As a result, collecting a series from each of the 4 fields took a total of 2 h per 96-well plate. This protocol was used for the primary screen, compound retesting, and dose response curves in [Figure 2](#F2){ref-type="fig"}, as well as for all experiments in [Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, and [6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}. During imaging, neurons were maintained in conditioned media at 37C and 5%CO~2~. In the primary screen the plate was incubated with Tetramethylrhodamine, methyl ester (TMRM, ThermoFisher Scientific, cat\#T668), and with Hoechst dye upon completion of the time-lapse sequence and then live-imaged again to determine mitochondrial membrane potential.

### Image Analysis {#S22}

In brief, data are processed by two CellProfiler pipelines: the first pipeline creates the minimum intensity projections of the time-lapse sequences, and the second pipeline employs the projections to create a mask of the stationary objects and performs the tracking of the motile objects using the Linear Assignment Problem method ([@R27]). The outcome of the Cell Profiler analysis was processed in MATLAB® (MathWorks, 1 Apple Hill Drive, Natick, MA 01760) using a custom script with a graphic user interface that represents data at the field and plate levels, creates heat-maps, and performs statistical computations such as Z-scores and KS statistics. TMRM levels were analyzed using ImageJ. Briefly, TMRM-labeled mitochondria were analyzed from areas of the wells lacking Mito-DsRed due to the low transfection efficiency. Cell bodies were outlined based on the Hoechst signal, and the intensity of TMRM per cell was quantified. 100-150 cells were analyzed per compound.

### Cortical Neuron Differentiation {#S23}

iPSCs were maintained in mTeSR-1 media (STEMCELL Technologies, \#85850) on Geltrex (ThermoFisher, \#A1413301), and passaged about once a week with Gentle Cell Dissociation Reagent (STEMCELL Technologies, \#07174), but were not used for differentiation past passage number 30. Cortical neurons were differentiated according to a protocol published by [@R67] with minor modifications described below. iPSCs (under passage 10 after karyotyping) were treated with Accutase (Innovative Cell Technologies, \#AT104) and plated at 90,000 cells/cm^2^ in mTeSR-1 media supplemented with 10uM ROCK inhibitor, Y-27632 (Cayman Chemical, \#10005583) on Geltrex-coated 12-well plates. On day 2, no mouse glia cells were added and we used Ara-C (Sigma-Aldrich, \#C1768) at a final concentration of 2uM. To label mitochondria in neurons, a lentivirus carrying CMV-Mito-DsRed was added to the media on day 5, supplemented with 8ug/mL polybrene (Sigma-Aldrich, \#TR-1003-G). Mitochondrial motility was assayed after day 14.

### Motor Neuron Differentiation {#S24}

The iPSC lines 39b SOD+/A4V and 39b SOD+/+The cells lines were differentiated between passage 8 to passage 14. Transfection with the HB9::GFP reporter was performed as described in [@R59]. A 1kb HB9 promoter fragment (gift from Hynek Wichterle) controlling the expression of myristoylated GFP was inserted into a donor plasmid specific for the AAVS1 locus (Sigma). Subsequently, 2.5 million iPS cells were single-cell dissociated using accutase and electroporated using the Neon transfection system (100ul tip; 1600V Voltage, 20ms Width, 1 Pulse; Life Technologies) with 2 g of AAVS1 ZFN plasmid and 6 g of modified AAVS1 donor plasmid. After nucleofection cells were plated on matrigel with mTeSR1 in the presence of ROCK inhibitor. After 48hrs, puromycin selection was applied and surviving clonal colonies were individually passaged and gDNA was extracted. PCR was used to confirm proper targeting of the cassette. Primer sequences are available upon request. Faithful expression of the reporter was verified using expression of the motor neuron marker Isl1 (Abcam (Ab109517), 1:1000) and the pan-neuronal marker Map2 (Milipore (MAB378), 1:1000). Stem cell cultures were differentiated into motor neurons as previously described in [@R32]. Briefly, iPSCs were dissociated to single cells and plated in suspension in low-adherence flasks (400k/mL), in mTeSR media with 10uM ROCK inhibitor. Media was gradually diluted (50% on day 3 and 100% on day 4) to KOSR (DMEM/F12, 10% KOSR) between days 1-4 and to a neural induction medium (NIM: DMEM/F12 with L-glutamine, NEAA, Heparin (2 ug/mL), N2 supplement (Invitrogen) for days 5-24. From days 1-6 cells were cultured in the presence of SB431542 (10 uM, Sigma Aldrich) and Dorsmorphin (1 uM, Stemgent), and from days 5-24 with BDNF (10 ng/mL, R&D), ascorbic acid (AA, 0.4 ug/mL, Sigma), Retinoic Acid (RA, 1 uM, Sigma) and Smoothened Agonist 1.3 (SAG 1.3, 1 uM, Calbiochem). On day 24 floating cell aggregates were dissociated into single cells with Papain/DNase (Worthington Bio) and HB9::GFP positive cells isolated using fluorescence activated cell sorting (FACS). Subsequently, 30k motor neurons were plated onto poly-D-lysine/laminin-coated 96 well plates together with 30k mouse primary glial cells (P1). Cell cultures were fed every 2-3 days with complete Neurobasal media containing L-glutamine, NEAA, glutamax, N2 and B27, with BDNF/CNTF/GDNF (10 ng/mL, R&D) and ascorbic acid (0.2 ug/mL, Sigma). After 14 days, the cultures were transduced with synapsin-MitoDSred lentivitrus and used for subsequent mitochondrial movement kinetics experiments.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S25}
---------------------------------------

### Statistical Analysis {#S26}

Statistical analysis was conducted in GraphPad Prism v6.0 and MATLAB®. Data were represented either using R (<https://www.R-project.org>) or GraphPad Prism v6.0 (GraphPad Software, 7825 Fay Avenue, Suite 230 La Jolla, CA 02037). If not indicated in the figures, \*\*\*\* = p \< 0.0001; \*\*\* = p \< 0.001; \*\* = p \< 0.01; \* = p \< 0.05; ns = p \> 0.05. Z-scores were calculated for each parameter using the formula Z = (x-μ)/σ. Because the values of integrated distance did not follow a normal distribution, we turned to the Kolmogorov-Smirnov (KS) statistic and used it as a descriptor ([@R45]). The KS statistic quantifies a distance between the distribution functions of samples, and is one of the most useful nonparametric methods for comparing two samples, as it is sensitive to differences in both location and shape of cumulative distribution functions, in this case distances traveled by each mitochondrion in the fields. No difference between distributions leads to KS = 0, while significant changes in the curves generate KS \> 0. We then transformed the KS values per well into Z-scores.

DATA AND CODE AVAILABILITY {#S27}
--------------------------

The datasets (primary screen data) as well as codes generated during this study are available at GitHub:

<https://github.com/ThomasSchwarzLab/ScreeningData_Shlevkov_CellReports_2019>

<https://github.com/ThomasSchwarzLab/ArrayScanCodes>

<https://github.com/ThomasSchwarzLab/KymolyzerCodes>
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![High-Content Assay to Screen for Regulators of Axonal Mitochondrial Trafficking\
(A) Rat hippocampal neurons transfected with Mito-DsRed to label mitochondria showing the original channel (left) and the masked channel (right) in which large objects such as somata and cell debris have been eliminated.\
(B) Representative image of a portion of the time-lapse series where a mask based on minimum intensity projection is used to identify stationary (outlined in green) mitochondria. These mitochondria are subtracted from the image to facilitate tracking of the motile objects (orange).\
(C) Time-lapse sequence of a small portion of an imaged field, with stationary (red) and motile (green) mitochondria identified based on the minimum intensity projection. Objects that exhibit significant movement are marked with an arrow.\
(D) Results of tracking of mitochondria in the field shown in (C). A threshold for a minimum amount of movement has been applied to classify "wiggling" mitochondria as stationary, and the "bona fide" motile mitochondria have been tracked using LAP algorithms (blue lines). Arrows indicated the tracks that represent the motile mitochondria identified in (C). See also [Video S2](#SD3){ref-type="supplementary-material"}.\
(E). Graphic representation, as in (D), of mitochondrial tracks in neurons either treated with DMSO(mock) or 1 μM calcimycin. Calcimycin reduced movement (blue lines) and increased the number of stationary objects (red dots).\
(F) Percent motile mitochondria as quantified by the CellProfiler pipeline, represented as Tukey's box plot, and a heatmap of *Z* scores that was created using PATHS (see [STAR Methods](#S9){ref-type="sec"}).\
(G) Integrated distance of the tracked objects expressed as cumulative distribution plots to compare either two sets of DMSO-treated cultures (top) or DMSO versus calcimycin cultures (bottom). Heat maps are shown for KS values that compare the distributions of integrated distances. The displacement parameter was similarly altered by calcimycin (KS value \~0.3; *Z* score \~19).\
(H, I, and J) Same analyses and representation as in (E), (F), and (G), respectively, but for a comparison between murine *SNPH*^+/+^ and *SNPH*^−/−^ neurons. Two-tailed t test was used to obtain p values in (F) and (I) upon determination of normality on D'Agostino-Pearson test.](nihms-1542901-f0001){#F1}

![Compound Screen and Identification of Hits\
(A and B) 2D plots where each axis corresponds to one replicate of the library of *Z* scores (KS of integrated distance) obtained in the screen. The cutoff levels of *Z* score = 3 are marked as dotted lines. Red box in (A) represents enlarged data in (B). Compounds that enhanced (green) or suppressed (red) transport were defined as hits if their KS of integrated distance was equal to or above Z = 3. Non-hits are gray. Enlargement in (B) shows the location of the hits that increased mitochondrial trafficking. The correlation coefficient for the two replicates was 0.75 (including positive and negative controls and test compounds) or 0.38 (test compounds only).\
(C) *Z* scores for all three parameters for each confirmed enhancer of motility. Red dotted line corresponds to *Z* score = 3\
(D-I) For each confirmed hit, the effect on the percent of motile mitochondria is shown together with a dose-response curve, for which the enhancement of motility was expressed as a percent of maximal enhancement. Panels correspond to Latrunculin B (D), Cytochalasin B (E), Ala-Ala-Phe-CMK (F), BMS-754807 (G), Hesperadin (H), and TAK-901 (I).\
Error bars in (C) represent SDs. Data represented in (D)--(I) as Tukey's box plots as well as normalized dose-response curves, where error bars represent SD. Two-tailed t test was used to obtain p values. n = 3 wells/plate from a minimum of two plates for (D)--(I).](nihms-1542901-f0002){#F2}

![TPP1 Is the Relevant Substrate of AAF-CMK\
(A) Known cellular targets of AAF-CMK.\
(B and C) *Z* score of percent motile (B) and KS integrated distance (C) in neurons transfected for at least 3 days with either scrambled or TPP2 shRNA (TPP2-i) and treated with 10 μM AAF-CMK 1 h prior to and during time-lapse imaging. TPP2-i neither mimicked nor occluded the effect of AAF-CMK.\
(D and E) Lack of effect of 2-h incubation with TPP2 inhibitor butabindide at 10 μM (D) and proteasome inhibitor carfilzomib at 5 μM (E) on percent motile and lack of dose-dependent response.\
(F and G) *Z* scores for percent motile (F) and KS integrated distance (Id) (G) in wells transduced either with scrambled shRNA or with TPP1 shRNAs and treated with either solvent or 10 μM AAF-CMK for 2 h before time-lapse imaging. Two non-overlapping sequences targeting TPP1 were used (TPP1-i 1 and 2) (*Z* scores of KS displacement were similar).\
(H) Effect of TPP1 over expression (OE) on the three motility descriptors.\
At least 4 wells per condition (each well representing the traces collected from more than 10,000 mitochondria) were used for the calculation of *Z* scores. Statistical significance between groups of *Z* scores was determined using an unpaired two-tailed t test. \*\*\*\*p \< 0.0001; \*\*\*p \< 0.001; \*\*p \< 0.01; \*p \< 0.05; ns = p \> 0.05. Data in all panels represented as Tukey's box plots.](nihms-1542901-f0003){#F3}

![Aurora B is the Target of the Kinase Inhibitor Class of Hits\
(A) *Z* score of percent motile in neurons transfected with either scrambled or Aurora Kinase B shRNA and treated with 3 μM Hesperadin 1 h prior to and during time-lapse imaging.\
(B) *Z* score of percent motile in neurons transfected with either scrambled or Aurora Kinase A shRNA and treated with 3 μM Hesperadin 1 h prior to and during time-lapse imaging.\
(C) Representative image of mitochondrial traces in a field of neurons either transfected with scrambled shRNA or with Aurora Kinase B shRNA.\
(D) Percent of motile mitochondria per well in neurons expressing either scrambled shRNA or shRNA against Aurora Kinase B.\
(E and F) *Z* scores of KS-integrated distance of neurons treated as in (A) and (B), respectively.\
(G) Integrated distance of mitochondrial traces in a representative well either transfected with scrambled shRNA or shRNA against Aurora Kinase B represented as a histogram and as a cumulative distribution. Each dot in the histogram corresponds to a single mitochondrial trajectory.\
(H) Dose-response curve of the effect of Barastertib on percent motility; values were normalized to the maximum percentage motility at 2 μM Barastertib.\
(I) *Z* score of percent motile of rat AurKB-i in combination with either wild-type (WT) or a kinase dead form of the RNAi-resistant human Aurora Kinase B.\
(J) Representative images of mitochondrial traces in a field of neurons either transfected with empty plasmid or with a plasmid expressing rat Aurora Kinase B.\
(K and L) Effect of Aurora Kinase B overexpression on percent motility (K) and integrated distance traveled (L).\
At least 4 wells per condition (each well containing traces collected from over 10,000 mitochondria on average) were used for the calculation of *Z* scores. Statistical significance between groups of *Z* scores was determined using an unpaired two-tailed t test. \*\*\*\*p \< 0.0001; \*\*\*p \< 0.001; \*\*p \< 0.01; \*p \< 0.05; ns = p \> 0.05. Data in (A), (B), (D)--(F), (I), and (K) represented as Tukey's box plots. Data in (G) and (L) represented as dot-plots and cumulative distributions of integrated distance, and p values are given for Mann-Whitney test. Dispersion bars in (H) represent SD.](nihms-1542901-f0004){#F4}

![Kymography of Aurora Kinase B Inhibition of Axonal Mitochondrial Transport\
(A) Representative kymographs of segments of an axon expressing Mito-DsRed treated with 3 μM Hesperadin or DMSO for 1 h prior to and during the imaging. Mitochondrial trajectories during the time-lapse movie (\~3 min) correspond to white lines with location represented along the x axis and time proceeding downward along the y axis. Diagonal lines indicate moving mitochondria, with retrograde movement to the left and anterograde movement to the right.\
(B) Hesperadin effect on percent of motile mitochondria per segment of axon as well as the average time a mitochondrion spends in motion represented as histograms as well as cumulative distribution curves.\
(C and D) Effects of Hesperadin on the direction of mitochondrial movement expressed as percent time in motion (C) and overall percent of events (D).\
(E) Density of all mitochondria (motile+stationary) per μM of axon as well as density of only stationary mitochondria per μM of axon.\
(F--J) Neurons transfected with either scrambled shRNA or shRNA against Aurora Kinase B analyzed as in (A)--(E).\
(F) Representative kymographs of segments of an axon expressing Mito-DsRed and Aurora Kinase B shRNA or scrambled shRNA.\
(G) Effect of shRNA against Aurora Kinase B on percent motile mitochondria per segment of axon, as well as the average time a mitochondrion spends in motion, represented as histograms as well as cumulative distribution curves.\
(H and I) Effect of shRNA on the direction of mitochondrial movement expressed as percent time in motion (H) and overall percent of events (I).\
(J) Density of all mitochondria (motile+stationary) per μM of axon as well as density of only stationary mitochondria per μM of axon.\
At least 100 mitochondria from at least 9 axons coming from three independent transfections were used for all quantifications. D, DMSO; H, Hesperadin; s, scrambled; and i, shRNA against Aurora Kinase B. Scale bars, 10 μM. Data in (B) (percent motile) and (E) and (G) (percent motile) represented as Tukey's box plots. Dispersion bars in (B) (time spent in motion) and (G) (time spent in motion) represent SD. Mann-Whitney test was used to obtain p values upon determination of normality on D'Agostino-Pearson test.](nihms-1542901-f0005){#F5}

![Activity of Hits in Human iPSC-Derived Neurons\
(A) Representative images of control iPSCs differentiated by neurogenin2-induction into cortical neurons. Nuclei were labeled with Hoechst 33258. GFP expression is driven by viral overexpression alongside the neurogenin2 vector. Neurons were labeled with β3-tubulin (red) to label all somata and neurites. Scale bar, 400 μm.\
(B and C) *Z* scores of percent motile (B) and KS values of integrated distance (C) for mitochondrial transport in human cortical neurons transduced with CMV-Mito-DsRed and treated with 3 μM Hesperadin, 1 μM Latrunculin A, and 10 μM AAF-CMK for 1 h before and during time-lapse imaging.\
(D and E) Kymographs were used to establish the average time a mitochondrion spends in motion (D) as well as its direction (E) in human cortical neurons transduced with CMV-Mito-DsRed and treated with either DMSO or Hesperadin.\
(F) Generation and differentiation of human motor neurons from induced pluripotent stem cells (iPSCs) derived from an ALS SOD1^+/A4V^ patient and from isogenic TALEN-corrected cells. HB9-GFP positive motor neurons were isolated by flow cytometry and co-cultured with mouse primary glial cells for 14 days. These cells maintained their motor neuron identity as indicated by Isl1 expression. Scale bar, 100 μm.\
(G and H) *Z* scores of percent of motile mitochondria (G) and KS value of integrated distance (H) in +/A4V neurons and +/+ isogenic control motor neurons.\
(I) Effect of Hesperadin, Latrunculin, and AAF-CMK on percent of motile mitochondria in +/A4V motor neurons.\
(J and K) Average time a mitochondrion spends in motion in +/A4V neurons treated with DMSO or with 3 μM Hesperadin represented as histograms (J) or as cumulative distribution plots (K).\
Dispersion bars in (B)--(E), (I), and (J) represent SD. Data in (G) and (H) are represented as Tukey's box plots. Mann-Whitney test was used to obtain p values upon determination of normality on D'Agostino-Pearson test.](nihms-1542901-f0006){#F6}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                                                                         SOURCE                                      IDENTIFIER
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------
  Antibodies                                                                                                                                                                                              
  Mouse anti-beta3-tubulin                                                                                                                                    Millipore Sigma                             T8660; RRID:AB_477590
  Rabbit anti-TPP1                                                                                                                                            Abcam                                       Ab96498, RRID; AB_10680725
  Mouse αnti-Myc, clone 4A6                                                                                                                                   EMD Millipore                               05724, RRID; AB_309938
  Rabbit monoclonal anti-Isl1                                                                                                                                 Abcam                                       Ab109517, RRID; AB_10866454
  Mouse anti-MAP2A,2B                                                                                                                                         EMD Millipore                               MAB378, RRID; AB_94967
  Bacterial and Virus Strains                                                                                                                                                                             
  CMV-mitoDSred LV                                                                                                                                            Orian Shririhai, UCLA                       N/A
  Synapsin-mitoDSred LV                                                                                                                                       This study                                  N/A
  pTet-O-Ngn2-puro                                                                                                                                            [@R67]                                      <https://www.addgene.org/52047/>
  Tet-O-FUW-EGFP                                                                                                                                              [@R58]                                      <https://www.addgene.org/30130/>
  FUW-M2rtTA                                                                                                                                                  [@R23]                                      <https://www.addgene.org/20342/>
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                           
  Biomol ICCBL -- 2012 library (480)                                                                                                                          ICCB-Longwood                               <https://iccb.med.harvard.edu/biomol-iccb-l-known-bioactives-2012>
  Selleck Bioactive compound library (1,902)                                                                                                                  ICCB-Longwood                               <https://iccb.med.harvard.edu/selleck-bioactive-compound-library>
  Calcimycin                                                                                                                                                  Millipore Sigma                             A23187
  Latrunculin B                                                                                                                                               Tocris                                      Cat \# 3974
  Latrunculin A                                                                                                                                               Tocris                                      Cat \# 3973
  Cytochalasin B                                                                                                                                              Tocris                                      Cat \# 5474
  Ala-Ala-Phe-CMK                                                                                                                                             Enzo                                        BML-PI123-0025
  BMS-754807                                                                                                                                                  Selleck Chemicals                           Cat \# S1124
  Hesperadin                                                                                                                                                  Selleck Chemicals                           Cat \# S1529
  TAK-901                                                                                                                                                     Selleck Chemicals                           Cat \# S2718
  Barasertib                                                                                                                                                  Selleck Chemicals                           Cat \# S1147
  Paclitaxel                                                                                                                                                  Tocris                                      Cat\# 1097
  24(S)-Hydroxycholesterol                                                                                                                                    Millipore Sigma                             Cat \# SML1648
  Butabindide oxalate                                                                                                                                         Tocris                                      Cat\# 1323
  Carfilzomib (PR-171)                                                                                                                                        Selleck Chemicals                           Cat \# S2853
  Y-27632(ROCK inhibitor)                                                                                                                                     Cayman Chemicals                            Cat\# 10005583
  Tetramethylrhodamine, methyl ester                                                                                                                          ThermoFisher                                Cat \#T668
  Deposited Data                                                                                                                                                                                          
  Primary screen data were deposited at GitHub                                                                                                                This study                                  <https://github.com/ThomasSchwarzLab/ScreeningData_Shlevkov_CellReports_2019>
  Experimental Models: Cell Lines                                                                                                                                                                         
  HEK293T                                                                                                                                                     ATCC                                        ATCC CRL-3216, RRID:CVCL_0063
  GON0515-03 \#5 iPSC line                                                                                                                                    This study                                  N/A
  39b SOD+/A4V iPSC line                                                                                                                                      [@R59]                                      N/A
  39b SOD+/+ iPSC line                                                                                                                                        [@R59]                                      N/A
  Experimental Models: Organisms/Strains                                                                                                                                                                  
  Syntaphilin KO mouse                                                                                                                                        [@R31]                                      N/A
  Oligonucleotides                                                                                                                                                                                        
  Primer AurkB K106R (forward): GTGGCGTCAGGGTCCTCTTG                                                                                                          This study                                  N/A
  Primer AurkB K106R (reverse): GATGAAATGGCTTTTCTTCTCCC                                                                                                       This study                                  N/A
  Primer synapsin-mitoDSred Lenti (forward): GCCTGAGAGCGCAGTAGCGCTACCGGACTCAGA                                                                                This study                                  N/A
  Primers for synapsin-mitoDSred Lenti (reverse): CCGCTAGCTTCGAAGATTATGATCTAGAGTCGCGGC                                                                        This study                                  N/A
  Recombinant DNA                                                                                                                                                                                         
  Mito-DsRed (pDsRed2-Mito)                                                                                                                                   G. Hajnoczky, Thomas Jefferson University   N/A
  GFP-rab7 WT                                                                                                                                                 [@R11]                                      Addgene \#12605
  pLV-CMV-mitoDSred                                                                                                                                           This study                                  N/A
  pLV-Synapsin-mitoDSred                                                                                                                                      This study                                  N/A
  pGFP-C-shLenti-Tpp1 (rat)                                                                                                                                   OriGene                                     TL711322
  pCMV6-Myc-DDK-Tpp1 (human)                                                                                                                                  OriGene                                     RC204471
  pGFP-C-shLenti-Tpp2 (rat)                                                                                                                                   OriGene                                     TL711260
  pGFP-C-shLenti-Aurkb (rat)                                                                                                                                  OriGene                                     TL712117
  pCMV6-Myc-DDK-Aurkb (human)                                                                                                                                 OriGene                                     RC210288
  pCMV6-Myc-DDH-AurkBK106R (kinase dead)                                                                                                                      This study                                  N/A
  pGFP-C-shLenti-Aurka (rat)                                                                                                                                  OriGene                                     TL320538
  Software and Algorithms                                                                                                                                                                                 
  ImageJ                                                                                                                                                      [@R52]                                      <https://imagej.nih.gov/ij/>
  MATLAB®                                                                                                                                                     MathWorks                                   <https://www.mathworks.com>
  CellProfiler                                                                                                                                                [@R3]                                       <https://cellprofiler.org>
  R                                                                                                                                                           [@R46]                                      <https://www.R-project.org>
  GraphPad Prism v6.0                                                                                                                                         GraphPad Software                           <https://www.graphpad.com>
  Other                                                                                                                                                                                                   
  Cell Profiler pipeline for motility analysis and PATHS: MATLAB-based code for processing of Cell Profiler data for motility analysis, deposited at GitHub   This study                                  <https://github.com/ThomasSchwarzLab/ArrayScanCodes>

###### Highlights

-   High-content imaging and object tracking enables a screen for mitochondrial motility

-   Aurora Kinase B or TPP1 inhibition or knockdown enhanced axonal transport of mitochondria

-   Actin depolymerization enhanced axonal transport of mitochondria

-   Hit compounds improve mitochondrial transport in SOD1^+/A4V^ ALS patient-derived neurons
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